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Background: There is a growing body of literature describing the properties of marketed drugs, the concept of
drug-likeness and the vastness of chemical space. In that context, enumerative combinatorics with simple atomic
components may be useful in the conception and design of structurally novel compounds for expanding and
enhancing high-throughput screening (HTS) libraries.
Results: A random combination of mono- and diatomic carbon, hydrogen, nitrogen, and oxygen containing
components in the absence of molecular weight constraints but with the ability to form rings affords virtual
compounds that fall in bulk physicochemical space typically associated with drugs, but whose ring assemblies fall
in new or under-represented areas of chemical shape space. When compared against compounds in the
ChEMBL_14, MDDR, Drug Bank and Dictionary of Natural Products, the percentage of virtual compounds with a
Tanimoto index of 1.0 (ECFP_4) was found to be as high as 0.21. Depending on therapeutic target, this value may
be in range of what might be expected from an experimental HTS campaign in terms of a true hit rate.
Conclusion: Virtual compounds derived through enumerative combinatorics of simple atomic components have
drug-like properties with ring assemblies that fall in new or under-represented areas of shape space. Structures
derived in this manner could provide the starting point or inspiration for the design of structurally novel scaffolds
in an unbiased fashion.
Keywords: High-throughput screening, HTS, Combinatorics, Drug discovery, Drug space, Enumeration, Virtual
compound librariesBackground
Contemporary small molecule drug discovery often relies
on high-throughput screening (HTS) of either structurally
diverse or mechanistically focused compound library sets
to identify hits that have the potential for multiparameter
optimization against biological targets of interest. Critical
to the success of this approach is the availability of com-
pounds in biologically relevant, druggable chemical space
[1,2]. However, the concept of what constitutes a druggable
chemical lead is evolving as more synthetically challenging
molecules prepared through either semi- (e.g., YondelisW,
IxempraW) or total synthesis (e.g., HalavenW, AplidinW) pass
through the clinical development pipeline to become
marketed drugs. In recent years, for example, diverted
total synthesis [3], diversity-oriented synthesis (DOS) [4]
and biology-oriented synthetic (BIOS) [5] approaches haveCorrespondence: melvin_yu@eisai.com
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reproduction in any medium, provided the orprovided compounds for biological evaluation that possess
increasing levels of structural and stereochemical com-
plexity. Non-traditional lead-like molecules now include,
for example, macrocyclic derivatives, which have been de-
scribed in the literature as an underexploited structural
class for drug discovery [6]. Finally, since natural products
span regions of chemical space not represented by bio-
active medicinal chemistry compounds [7], their scaffolds
may serve as the inspiration for the design of structurally
novel combinatorial libraries [8].
The goal of these efforts is to move into new or
underexplored areas of chemical space with the expect-
ation of finding activity against difficult to target protein
systems with structurally novel compounds [9]. Since the
pioneering work of Lipinski and co-workers [10], there
has been an increased focus on bulk physicochemical
properties of both leads and drug candidates as well as a
better appreciation for drug space [11] in the context of
the much larger chemical space [12]. Studies exploringis is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to the development of large virtual compound libraries
through in silico combinatorial multiplexing [13,14].
While exhaustive libraries of this type have their place
in virtual screening, the development of smaller dynamic
virtual libraries focused on a particular mechanistic class
may also contribute toward the identification of viable
chemical leads.
Drug discovery, on the other hand, involves more than
just interrogating proteins to identify small molecules
that bind and invoke a functional response in vitro. It is
typically a process of which hit identification marks just
the beginning. The subsequent hit-to-lead evaluation
and the success of lead optimization to identify a clinical
candidate are critically dependent on the quality of the
initial screening hit. In the extreme, if one limits the
process to compound libraries with known activity and
only screens against biological targets of known function
using known methodology, then there is little need for
innovation. Furthermore, past success may not necessarily
predict future success [15,16]. Since complex interactions
among protein systems may need to be modulated in
the context of a disease state, new chemotypes may be
required to enhance the arsenal of known scaffolds to
explore new biological target engagement opportunities,
and therefore drug discovery opportunities, in areas of
unmet medical need.
While there are many complementary strategies to
expand and enhance an existing screening library, one
among several that we considered was the role of ran-
domness in molecular assembly at the atomic level. We
therefore decided to examine the importance of stochastic
processes on molecular design, in particular, ring assem-
blies for identifying structurally novel biogenic-like scaf-
folds. Used in tandem with predictive in silico biological
models as part of an iterative loop (i.e., enumerate, evalu-
ate in silico, adjust enumeration conditions, repeat until
convergence criteria satisfied), new structures could po-
tentially be “evolved” in silico and used as the inspiration
for structurally novel scaffold design. In this manner,
virtual compounds could be generated in an unbiased
fashion and filtered by in silico mechanistic models (e.g.,
kinases, GPCRs, PPIs, etc.) to create dynamic, structurally
novel, mechanism-based screening libraries.
Results
In this study, known druggable space (KDS) was defined
as the union of compounds found in the ChEMBL_14
[17], MDL/SYMYX Drug Data Report (MDDR release
2007.2) and DrugBank [18] databases with duplicate
structures removed. Using a molecular enumerator de-
veloped in this laboratory [19], a total of 250,000 virtual
compounds was generated from a carbon atom as the
core with simple mono- and diatomic fragments addedin a stochastic manner. As expected, analysis of the KDS,
Dictionary of Natural Products (DNP) and enumerated
sets indicate that the collection of randomly generated
virtual compounds resembles that of the DNP with re-
spect to the ratio of carbon, nitrogen and oxygen atoms
present in each molecule, but with a narrower molecu-
lar weight range (Figure 1). This is a direct consequence
of the larger number of oxygen containing fragments
available for enumeration, where only one of the ten
fragments contains a nitrogen atom.
Interestingly, physicochemical property analysis reveals
that a majority of the randomly generated virtual com-
pounds falls in the range of generally accepted drug space
(Figure 2), despite starting with a single carbon atom as
the core and using only ten simple fragments. Here, the
objective was not to explore all of possible chemical space,
but to generate virtual compounds that could serve as the
starting point or inspiration for designing structurally
novel scaffolds. Of the enumerated structures, 99.6% have
a MW less than 500 and 86% have a MW between 200
and 500 (Figure 3). By requiring the molecular polar sur-
face area (PSA) to be greater than zero and less than
140 Å2, 83% of the enumerated structures fall in the MW
range 200–500 (Figure 4). Furthermore, over 95% of the
enumerated structures are both Lipinski [10] and Veber
[20] rule compliant suggesting that a vast majority of the
randomly generated virtual compounds possess physico-
chemical properties in the range appropriate for passive
transcellular permeability with the possibility of oral ab-
sorption. Since each molecule grows in a stochastic and
independent manner, the average molecular weight of
the virtual set should not be dependent on the number
of compounds enumerated. Monitoring the average mo-
lecular weight for each group of 10,000 compounds gen-
erated in sequence indicates no statistically significant
differences between the groups (Figure 5A). Similarly,
the average molecular weight over time does not change
as the enumerated set grows from 10,000 to 250,000
members (Figure 5B).
Multi-fusion similarity analyses [21] of compounds in
the KDS, DNP and enumerated sets further substantiate
the conclusion that the virtual compounds resemble both
of the former sets in terms of physicochemical properties
(Figure 6A). Differences were noted, however, with respect
to Tanimoto indices using ECFP_4 circular fingerprints
(Figure 6B) [22]. Thus, the enumerated set differs struc-
turally from both KDS and DNP compounds, but exhibit
similar bulk physicochemical properties as evidenced by
the average minimum Euclidean distance. These results
suggest that the enumerated compounds are both struc-
turally unique and drug-like in terms of their predicted
properties. Inspection of Figure 6B reveals that a small
percentage of the enumerated compounds exhibit a
Tanimoto index of unity when compared against both
Figure 1 MW histogram plots for the DNP (green) and enumerated (red) sets. (A) Whole molecule comparison. (B) Ring assembly comparison.
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pounds, 410 (0.16%) were found to meet this criterion.
To explore similarities that may exist in terms of mo-
lecular scaffolds, each of the three compound sets was
reduced to a collection of ring assemblies using Pipeline
Pilot [23] where original alpha atom attachments were
maintained. In this manner, 95,522 different assemblies
were identified from the enumerated set. Of these, 255Figure 2 Histogram analysis of the 250,000 member enumerated virt(0.27%) were found to be common with ring assemblies
derived from either the KDS or the DNP sets.
Using the principal moment of inertia (PMI) method
of Sauer and Schwarz [24], considerable overlap was
found to exist between the KDS and DNP ring assembly
sets with respect to their 2D binned kernel density esti-
mates. In contrast, the enumerated ring assemblies
were found to occupy a much broader region centeredual compound set.
Figure 3 Cumulative plot of enumerated virtual compound
numbers as a function of MW.
Figure 5 MW plots of enumerated compounds (mean ± SD).
(A) For each sequential group of 10,000 enumerated compounds.
(B) As a function of the number of compounds enumerated.
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space isosceles triangle (Figure 7).
To determine if the KDS and DNP ring assembly sets
could be better differentiated from each other, an alter-
native method to assess and visualize molecular shape
distribution in compound collections was investigated.
Borrowing from the field of petrology, we explored a
method originally developed to describe the shape of
aggregates, material used to form the base coarse layer
of roads [25]. In this approach, only the object’s degree
of sphericity (ψ) and length along three major orthogonal
axes would be needed. To accomplish this, we used
shadow area and PMI as two different indices of molecular
length. The elongation (p) and flatness (q) parameters,
which are independent of molecular size, could then beFigure 4 Plot of MW vs. polar surface area for the enumerated
virtual compound set.calculated using equations 1 and 2, respectively. Molecular
sphericity could be calculated using equation 3.
p ¼ small value=medium value either shadow area or PMIð Þ
ð1Þ







r !2 !=SASA ð3Þ
Where:
SAVol = 3D surface area volume
SASA = 3D solvent accessible surface area
The KDS ring assembly set was used to build a PCA
model using the five shape descriptors (p_shadow_area,
p_PMI, q_shadow-area, q_PMI, and ψ) as independent
parameters. The minimum and maximum values for the
first two principal components calculated from the KDS
and DNP sets were then used to scale the first two
principal component values calculated for all of the ring
assemblies. These were mapped onto a 50x50 grid, where
the z-axis was taken to represent the frequency found in
each square of the grid. A graph of these values revealed a
better separation between ring assembly shapes found in
the KDS and DNP sets (Figure 8). In this analysis, the
randomly enumerated virtual compounds fall within
Figure 6 Multi-fusion similarity maps plotting the virtual enumerated set against KDS (red) and DNP (green) as the reference sets.
(A) Euclidean distances using physicochemical properties MW, PSA, AlogP, HBA, HBD, RotB. (B) Tanimoto indices using ECFP_4.
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more closely resembling that of the DNP.
Scaffold diversity of the randomly enumerated com-
pounds was assessed by calculating the Tanimoto distance
(ECFP_4) for each ring assembly against all others in the
set. For comparison, Tanimoto distances for the KDS
and DNP sets were similarly calculated. While all three
of the compound arrays were found to be internally
structurally diverse with median Tanimoto distances less
than 0.2, the enumerated set appears to be slightly less
so than the other two (Figure 9A). This is likely a conse-
quence of the enumeration fragments being limited to
carbon, hydrogen, nitrogen and oxygen atoms with no
halides, phosphorous, sulfur or other heteroatoms allowed.
The ring assembly analysis was then repeated, but in the
absence of alpha atoms (Figure 9B). The results were
very similar, again indicating a high degree of internal
structural diversity. A sampling of intersecting ring sys-
tems appears in Figure 10 and a sampling of unique ring
systems from the complement of the enumerated set
appears in Figure 11.Figure 7 PMI ring assembly shape distribution plot. (A) KDS, (B) DNP aAs expected, compounds in the enumerated virtual set
exhibit a high degree of saturation with a mean ratio of
sp3 hybridized carbons to total number of carbon atoms
equal to 0.71 ± 0.22 (mean ± SD). In contrast, compounds
in the KDS set exhibit a mean ratio of 0.34 ± 0.21. A simi-
lar difference was noted with their associated ring assem-
blies (original alpha atoms allowed), thereby suggesting
that the enumerated scaffolds may possess an enhanced
level of three-dimensional character relative to the KDS
compounds. Since ring assemblies in the DNP exhibited a
mean ratio of 0.61 ± 0.30, the enumerated compounds
more closely resemble natural products in terms of their
overall percentage of sp3 hybridized carbon atoms, which
is to be expected given that all but two of the fragments
available for enumeration are saturated.
To increase the amount of unsaturation in the enu-
merated structures, an olefin was added to the fragment
set. A total of 250,000 virtual compounds was generated
and analyzed as described earlier. Both the bulk physico-
chemical properties of the enumerated molecules and the
shape distribution of the corresponding ring assembliesnd (C) enumerated set.
Figure 8 Principal component ring assembly contour map using coarse aggregate shape descriptors p, q, and ψ. The z-axis represented
by the green to red color spectrum is the frequency of ring assemblies falling in that shape region. (A) KDS, (B) DNP and (C) enumerated set.
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adding unsaturation in the form of non-aromatic double
bonds did not alter either the calculated bulk physico-
chemical properties of the virtual compounds or the shape
of the corresponding ring assemblies.
The effect of allowable ring formation modes was then
investigated with respect to the type of compounds gen-
erated (Figure 12). In these runs either the intra-chain
mode of ring formation or the inter-chain mode was
deactivated. The bulk physicochemical properties for the
two modified enumerations were again found to be very
similar indicating that the ring forming mode did not
impact the calculated properties of the virtual compounds
(see Additional file 1). Allowing both ring forming modes
to take place afforded structures of which 95% were both
Lipinski and Veber rule compliant. Similarly, allowing only
the intra-chain or the inter-chain modes to occur in separ-
ate runs gave structures that were 86% and 96% compli-
ant, respectively. When compared against the KDS andFigure 9 Violin plots of the Tanimoto similarity distance using ECFP_
in its respective set. (A) KDS, DNP and enumerated virtual compound ring
plot as before, but in the absence of alpha atoms.DNP sets using ECFP_4 fingerprints, the 250,000 virtual
compounds with the intra-chain option deactivated afforded
270 virtual “hits” (0.11%) with a Tanimoto index of 1.0.
For the set with the inter-chain option deactivated, a total
of 521 “hits” (0.21%) emerged.
For comparison, the random 1 million compound set
from the GDB13 database [14] was downloaded [26] and
analyzed. The average molecular weight for this set was
178 ± 10 (mean ± SD), whereas for the enumerated set of
250,000 compounds the average molecular weight was
264 ± 65. Other than the difference in average molecular
weight, the distribution of total polar surface area, AlogP,
number of rotatable bonds, number of hydrogen bond
donors and number of hydrogen bond acceptors was
similar across the two sets (see Additional file 1). With
regard to molecular shape, the ring assemblies associated
with the random 1 million GDB13 structures span the
region occupied by both the enumerated and DNP ring
assemblies (Figure 13).4. The distance was calculated for each ring assembly against all others
assembly sets with original alpha atom attachments allowed. (B) Violin
omsþ 1Þþlog10 nSpiroAtomsþ 1ð Þ
Centersþ 1Þþlog10 nMidLargeRingsþ 1ð Þ
romaticDoubleBondsþ 1Þ þ nHeavyAtomsð Þ1:005
s
Figure 10 Sampling of ring assemblies without alpha atoms common to the enumerated set and either KDS or the DNP.
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molecular complexity (MC) as calculated using an adapta-
tion of the method described by Ertl and Schuffenhauer
[27]. The resulting distribution was compared to that
found for the KDS and DNP sets. Inspection of Figure 14
indicates that disabling the inter-chain ring forming
mode afforded virtual compounds calculated to be more
like those in the KDS in terms of their MC score,
whereas disabling the intra-chain mode generated struc-
tures that more closely resembled those of the DNP.
Molecular Complexity MCð Þ score ¼ log10 nBridgeAtð
þlog10 nStereoð
þlog10 nNonAð
nHeavyAtomFigure 11 Sampling of structurally unique ring assemblies without alA number of different heteroaromatic ring systems
(pyridine, pyrimidine, indole, benzimidazole, purine, etc.)
were added to the fragment pool to allow these ring sys-
tems to be incorporated into the enumerated structures.
In this case, of the 250,000 virtual compounds 62% were
both Lipinski and Veber rule compliant despite an increase
in the average molecular weight of the set as a whole
(467 ± 194, mean ± SD). Thus, even with an expanded
fragment collection more than half of the enumerated com-
pounds fall within bulk physicochemical space generallypha atoms from the complement of the enumerated set.
Figure 12 Cartoon depicting two different ring forming modes
used by the enumerator. (1) Inter-chain ring formation between
growing chains A and B. (2) Intra-chain ring formation within
growing chain B.
Figure 14 Molecular complexity (MC) score distribution for the
KDS, DNP and enumerated sets.
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lecular complexity score for this group of virtual com-
pounds falls in-between that of the KDS and DNP sets,
and is similar to that of the random 1 million compound
GDB13 set (Figure 15).
Experimental
The KDS and DNP compounds were deglycosylated using
Pipeline Pilot prior to analysis. The enumerated sets were
generated as follows: A total of 250,000 virtual compounds
consisting of both acyclic and cyclic systems was randomly
generated from a single carbon atom in the absence of any
molecular weight (MW) constraints (either minimum or
maximum). The fragments appear in Table 1. Fragment
weights were scaled to according to the number of carbon
atoms found in the largest fragment.Figure 13 Shape distribution plots for random 1 million compounds
component ring assembly shape analysis.Discussion
Appropriate physicochemical properties are important
parameters for compounds to become drugs; they affect
the route of administration, pharmacokinetics, pharma-
codynamics, formulation and chemical stability of the
drug substance. Thus, it is critical during lead optimization
that these properties be either retained or optimized so that
the compound reaches its biological target with sufficient
exposure to elicit a functional response in vivo with an ac-
ceptable side effect profile. Starting with a lead compound
that already falls in accepted physicochemical drug space
will likely streamline the path to both in vivo proof of
concept and eventually clinical candidate selection. For
example, optimizing for CNS penetration involves multiple
parameters that include physicochemical properties [28].
The work by Lipinski and co-workers reinforced the
importance of physicochemical property space with regard
to oral drugs, which served to highlight that intrinsic
potency is just one of many parameters that must be
considered during lead optimization. Yet, potency is an
important factor that drives the choice of analogues tofrom GDB13. (A) PMI ring assembly shape analysis. (B) Principal
Figure 15 Molecular complexity score (MC) distribution for the
KDS, DNP, heterocyclic enumerated and GDB13 sets.
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[29]. As pioneered by Paul Ehrlich in the early 20th cen-
tury, compounds must interact with a biological target
to elicit a biological response. This interaction can be
explained by conventional chemical interactions and, in
a deterministic sense, reduced to a set of atomic features
consisting of electrostatics, hydrogen bonds, van der Waals,
hydrophobic and pi stacking interactions as well as
entropic considerations. Since biological targets (e.g., pro-
tein receptors, enzymes and DNA) are three-dimensional
structures, the interactions require appropriate comple-
mentary placement of the pharmacophoric groups in three-
dimensional space. Thus, biologically active molecules arise
as a consequence of appropriate pharmacophoric feature
pairing with their biological target(s). As a result, adequate
representation in shape space in addition to property spaceTable 1 Fragments used in the enumeration process [19]
Number Fragment Allow heteroatom
attachment
Enumeration weight
1 H yes 6
2 *CP yes 6
3 *CP,D,A yes 6
4 *NP no 6
5 *OT no 6
6 *OP no 6
7 *OD NA 6
8 P*C-O no 6
9 A*C = O yes 6
10 Phenyl (*C1,C2D) yes 1
11 *C = CP no 3
Note that a single atom can serve more than one function. It can be (1) the
point of initial attachment in a growing chain, (2) the point of propagation,
(3) a donor or acceptor ring forming node.
NA: Not applicable.
*Location of initial attachment to growing chain.
TTerminating node.
PPropagating node.
DRing forming donor node.
ARing forming acceptor node.will be important for a screening library to successfully
provide viable chemical leads for optimization and in vivo
proof of concept.
In this regard, the majority of natural product scaffolds
have been shown to be absent from commercially avail-
able compounds [30], consistent with the shape analyses
depicted in Figures 7 and 8. The directed expansion and
enhancement of existing HTS screening libraries for drug
discovery purposes could therefore be accomplished not
only through the addition of compounds biased toward
naturally occurring biogenic scaffolds (e.g., DOS or BIOS),
but also through the addition of biogenic-like scaffolds
derived from enumerative combinatorics of simple atomic
components. When compared with compounds from the
KDS and DNP sets, the enumerated compounds exhibited
a virtual “hit” rate as high as 0.21% (i.e., Tanimoto index =
1.0). Depending on therapeutic target, this value may be
similar to what might be expected from an experimental
HTS campaign in terms of a true hit rate.
The question then arises as to whether or not the
collection of molecular shapes associated with known
small molecule ligands will be sufficient to support future
drug discovery efforts that will likely include modulating
therapeutic targets for which there are currently no known
small molecule effectors. Since biologically active synthetic
compounds and natural products work with known sys-
tems, it logically follows that screening libraries could
be enhanced and expanded based on the concept of
privileged structures [31]. If, however, a subset of future
therapeutic targets requires ligands that possess molecular
shapes not represented by known drugs, then enhancing
screening libraries with compounds derived through enu-
merative combinatorics may be appropriate. In this sense,
the results of this study do not contradict the concept of
DOS and BIOS [32], but rather complements it in terms
of potential future unknown therapeutic target oppor-
tunities. Since the enumerator does not utilize chemical
reaction information in the construction of virtual com-
pounds, the resulting structures may point the way to
new scaffolds in unexplored areas of molecular shape
space. Thus, this approach may be complementary to
those that employ known chemical reactions and com-
mon molecular building blocks to generate virtual com-
pound libraries [33].
Since the molecular mass distribution of drugs is es-
sentially identical to that of all chemicals stored in the
Beilstein database, it’s tempting to speculate that ran-
domness may indeed play a role in drug design, i.e., that
drugs arise from a random sampling of existing sub-
stances defined by the rules of organic chemistry as pro-
posed by Fialkowski and co-workers [34]. Alternatively,
the overlapping molecular weight distribution of random
molecules and drug substances could be viewed as
additional evidence that physicochemical space is the
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ent of synthetic pathways.
During drug discovery, compounds that are found to
exhibit desirable biological activity are expanded upon
during the hit to lead and lead optimization phases,
while those that do not are either discarded or remain as
singletons. Since these analogues are usually retained in
the screening library, over time the collection can be-
come enriched in chemotypes associated with past pro-
grams, which may limit the probability of success with
therapeutic targets outside historical mechanistic classes.
In such cases, enumerative combinatorics in combination
with in silico biological models may represent one ap-
proach to enhance and expand existing screening libraries
in an unbiased fashion.
Conclusion
This study suggests that bulk physicochemical property
drug space could have arisen from enumerative com-
binatorics independent of synthetic pathway. Since natural
products are produced by organisms through biosynthetic
pathways and non-naturally occurring drug substances are
generally produced through chemical reactions performed
in the laboratory using different techniques and starting
materials, it might be expected that the two classes of
compounds differ from each other and can, in fact, be
distinguished on the basis of chemical fingerprints (e.g.,
HOSE codes) [35]. The enumerated molecules, however,
were constructed in a stochastic manner following neither
paradigm and yet are predicted to exhibit bulk physico-
chemical properties consistent with known biologically
active agents, whether they be naturally occurring or not.
Since these structures fall in new or under-represented
areas of shape space, virtual compounds derived through
enumerative combinatorics of simple atomic components
could provide the starting point or inspiration for the
design of structurally novel scaffolds in an unbiased fash-
ion that blur the line between synthetic substances and
natural products.
Additional file
Additional file 1: Figure S1. Histogram analysis of enumerated structures
with an olefin fragment included (see Experimental Section, Table 1 of the
manuscript for details). Figure S2. Histogram analysis of the GDB13 set
(1 million random compounds) as downloaded from the website.
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